Quick Answer
SPRUCE BIOSCIENCES, INC. reported Total Revenue of $0.00 for fiscal year 2025.
SPRUCE BIOSCIENCES, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$4.91M -51.3% |
$10.09M | $0.00 | — | — |
| Net Income | -$38.97M +26.5% |
-$53.04M -10.7% |
-$47.92M -3.8% |
-$46.18M -9.2% |
-$42.29M -43.2% |
-$29.54M -125.7% |
| Diluted EPS | -$50.83 +47.3% |
-$96.40 -7674.2% |
-$1.24 +36.7% |
-$1.96 -8.3% |
-$1.81 | — |
| Total Assets | $53.02M +17.3% |
$45.21M -56.5% |
$103.95M +21.4% |
$85.65M -32.3% |
$126.49M -22.3% |
$162.88M +3371.5% |
| Cash and Equivalents | $48.91M +26.2% |
$38.75M -59.8% |
$96.34M +293.4% |
$24.49M -42.7% |
$42.75M -72.8% |
$157.15M +3904.8% |
| Long-Term Debt | $0.00 -100.0% |
$124.0K -92.8% |
$1.72M -47.9% |
$3.29M -32.5% |
$4.88M +153.8% |
$1.92M -39.8% |
| Stockholders Equity | $42.52M +47.5% |
$28.82M -62.3% |
$76.51M +11.7% |
$68.49M -38.5% |
$111.37M -25.5% |
$149.43M +587.7% |
| R&D Expense | $19.52M -57.9% |
$46.42M -6.1% |
$49.43M +40.4% |
$35.20M +14.7% |
$30.70M +28.7% |
$23.85M +120.5% |
| Operating Income | -$36.51M +35.0% |
-$56.15M -8.0% |
-$51.99M -10.0% |
-$47.28M -12.4% |
-$42.07M -43.0% |
-$29.42M -124.4% |
| Shares Outstanding | 1.37M +143.7% |
563,042 -98.6% |
41.03M +73.8% |
23.60M +0.5% |
23.49M +1.0% |
23.26M +2942.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$8.21M | +5.3% | -297.3% |
| Diluted EPS | September 30, 2025 | -$14.58 | +7.4% | -316.6% |
| Total Assets | September 30, 2025 | $15.31M | -76.5% | -29.8% |
| Cash and Equivalents | September 30, 2025 | $10.67M | -82.2% | -34.9% |
| Long-Term Debt | September 30, 2025 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | $5.39M | -89.6% | -59.1% |
| R&D Expense | September 30, 2025 | $5.01M | -23.5% | +1265.3% |
| Operating Income | September 30, 2025 | -$8.23M | +12.5% | -205.7% |
| Shares Outstanding | September 30, 2025 | 563,491 | -98.6% | +0.1% |
- SPRUCE BIOSCIENCES, INC. reported Total Revenue of $0.00 for fiscal year 2025.
- SPRUCE BIOSCIENCES, INC. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- SPRUCE BIOSCIENCES, INC. reported Net Income of -$38.97 million for fiscal year 2025.
- SPRUCE BIOSCIENCES, INC. showed an increase of +26.5% in Net Income compared to the prior fiscal year.
- SPRUCE BIOSCIENCES, INC. reported Diluted EPS of $50.83 per share (loss) for fiscal year 2025.
- SPRUCE BIOSCIENCES, INC. showed an increase of +47.3% in Diluted EPS compared to the prior fiscal year.
- SPRUCE BIOSCIENCES, INC. reported Total Assets of $53.02 million for fiscal year 2025.
- SPRUCE BIOSCIENCES, INC. showed an increase of +17.3% in Total Assets compared to the prior fiscal year.
- SPRUCE BIOSCIENCES, INC. reported Cash and Equivalents of $48.91 million for fiscal year 2025.
- SPRUCE BIOSCIENCES, INC. showed an increase of +26.2% in Cash and Equivalents compared to the prior fiscal year.
- SPRUCE BIOSCIENCES, INC. reported Long-Term Debt of $0.00 for fiscal year 2025.
- SPRUCE BIOSCIENCES, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- SPRUCE BIOSCIENCES, INC. reported Stockholders Equity of $42.52 million for fiscal year 2025.
- SPRUCE BIOSCIENCES, INC. showed an increase of +47.5% in Stockholders Equity compared to the prior fiscal year.
- SPRUCE BIOSCIENCES, INC. reported R&D Expense of $19.52 million for fiscal year 2025.
- SPRUCE BIOSCIENCES, INC. showed a decrease of -57.9% in R&D Expense compared to the prior fiscal year.
- SPRUCE BIOSCIENCES, INC. reported Operating Income of -$36.51 million for fiscal year 2025.
- SPRUCE BIOSCIENCES, INC. showed an increase of +35.0% in Operating Income compared to the prior fiscal year.
- SPRUCE BIOSCIENCES, INC. reported Shares Outstanding of 1.37 million shares for fiscal year 2025.
- SPRUCE BIOSCIENCES, INC. showed an increase of +143.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: